WHO ATTENDS
Pharma, biotechs
TOPIC AREAS
- Patient centric clinical development
- Clinical trial design
- Real World Evidence in clinical development
- Expanded Access Programs / Managed Access Programs
WHO SHOULD SPONSOR
- Contract Research Organizations (CROs)
- Contract Development and Manufacturing Organizations (CDMOs)
- Clinical Trials Services - Home Clinical Trials
- Patient Recruitment & Identification
- Regulatory Consulting
WHO ATTENDS
Pharma, biotechs
Patient Advocacy Groups
TOPICS AREAS
- Patient Data
- Patient Registries & Patient Reported Outcomes (PROs)
- Evolving role of patient groups in R&D
- Genetic testing & diagnosis
- Advocacy & Policy
- Setting up patient groups
- Industry collaboration
WHO SHOULD SPONSOR
- Pharma & biotechs
- Research Institutions
- Patient Registries
- Patient Engagement Platforms
- Genetic Testing providers
- Genomic Sequencing Platforms
- Diagnostics
WHO ATTENDS
Pharma, biotechs
Technical Operations
TOPICS AREAS
- Gene therapy development
- Cell therapy development
- Translational science and path to clinical trials
- Regulation
WHO SHOULD SPONSOR
- Advanced therapies pharma & biotechs
- Gene Editing biotechs
- Contract Research Organizations (CROs)
- Clinical trial design
WHO ATTENDS
Pharma, biotechs
TOPICS AREAS
- Advanced therapies pricing & reimbursement
- Real World Evidence
- Health Technology Assessment
- Value Based Assessment
- Next generation pricing and innovative pricing models
WHO SHOULD SPONSOR
- PRO consultancies and PRO technology providers
- Value communication organizations
- Pricing & Reimbursement consulting firms
- HEOR service providers
- Patient registries and database providers
WHO ATTENDS
Pharma, biotechs
Hospitals and healthcare centers
Payers
TOPICS AREAS
- AI in drug discovery
- Patient identification
- Data analytics
- Data collection through wearables and applications
WHO SHOULD SPONSOR
- Artificial Intelligence platforms
- Patient identification solutions
- Machine learning
- Data analytics
- Wearable technology
- Digital Health Apps
- Patient registries
WHO ATTENDS
Pharma, biotechs
Venture Capital Firms
Grant Agencies (Public and Private)
Licensing pharma
TOPICS AREAS
- Advanced therapies investment
- Risk assessment
- Partnering and co-development opportunities
- Funding
- Accelerating orphan drug development
- Successful case studies
WHO SHOULD SPONSOR
- Advanced therapies investment
- Risk assessment
- Partnering and co-development opportunities
- Funders
WHO ATTENDS
Pharma, biotechs
TOPIC AREAS
- Business models
- Forecasting and Epidemiology
- Global expansion and internationalization
- Business development
WHO SHOULD SPONSOR
- Specialty Pharmacy
- Logistics, Supply Chain, 3PL
- Strategic Consulting
- Real World Evidence
- Forecasting and Epidemiology
- Marketing, Communications Agency
WHO ATTENDS
Pharma, biotechs
Rare Disease advocacy organizations
TOPIC AREAS
- Genetic counselling
- Industry partnerships
- Genomics
- Newborn Screening
- Access & Reimbursement of testing
WHO SHOULD SPONSOR
- Genetic testing companies
- Genetic counselling consulting
- Genomics companies
- Newborn screening providers
WHO ATTENDS
Pharma, biotechs
TOPIC AREAS
- Process development
- Outsourcing
- Viral vector development
- Manufacturing efficiency and capacity
- Analytical development
- Quality Control
WHO SHOULD SPONSOR
- Process development
- Outsourcing
- Viral vector development
- Manufacturing efficiency and capacity
- Analytical development
WHO ATTENDS
Pharma, biotechs
Regulators
Government
TOPIC AREAS
- Market entry strategies
- Stakeholder collaboration for market access
- Real World Evidence
- Improving access
- International regulation
WHO SHOULD SPONSOR
- Market entry strategies
- Stakeholder collaboration for market access
- Real World Evidence
- Improving access
- International regulation
WHO ATTENDS
Pharma, biotechs
TOPIC AREAS
- Discovery platforms
- Artificial Intelligence & Machine Learning applications
- Small molecule development
- Scientific innovations
- Collaborations
WHO SHOULD SPONSOR
- Drug discovery companies
- Artificial Intelligence and Machine Learning applications
- Predictive analytics platforms
- Contract Research Organizations (CROs)
WHO ATTENDS
Pharma, biotechs
TOPIC AREAS
- Diagnosis
- Biomarker R&D
- CAR-T development
- Advocacy and patient voice
- Clinical development and commercialization
WHO SHOULD SPONSOR
- Immunoncology pharma and biotechs
- Contract Manufacturing Organizations (CMOs)
- Contract Research Organizations (CROs)
- Genomic/DNA sequencing
On this seminar, payers from around the world will discuss approaches and strategies to improve pricing & reimbursement in rare diseases, including innovative pricing schemes and optimization of value-based assessments.
Learn about novel pipelines, approaches and candidates on the Next Generation Therapies Seminar, where someday these technologies and therapies could be the common place to treat rare diseases.
When developing therapies for rare and ultra-rare diseases the value of patient data is immensurable. Though patients and their families are usually willing to share their data to advance research being their individual causes, issues with data privacy, ownership, consent and handling are still a big hurdle impeding the progress of utilizing data to identify patients, shorten the time for an accurate diagnosis, build disease knowledge, expedite R&D, and enhance access to available therapies. assessments.